Showing results filtered by:
16 Results
Sample Application (R01): Troemel
https://www.niaid.nih.gov/sites/default/files/application-troemel-10-11-24.pdf
Last Reviewed: October 11, 2024
CMCRC Radiobiology Textbook - Chapter Seven
https://www.niaid.nih.gov/sites/default/files/cmcrc-radiobiology-textbook-chapter-seven.pdf
Last Reviewed: August 6, 2024
Sample Application (K08): Al-Adra
https://www.niaid.nih.gov/sites/default/files/1-k08-ai155816-01a1-aladra-application-508.pdf
Last Reviewed: September 13, 2024
CMCRC Radiobiology Textbook - Chapter Nine, Section L
https://www.niaid.nih.gov/sites/default/files/cmcrc-radiobiology-textbook-chapter-nine-section-l.pdf
Last Reviewed: August 6, 2024
CMCRC Radiobiology Textbook - Chapter Ten, Section D
https://www.niaid.nih.gov/sites/default/files/cmcrc-radiobiology-textbook-chapter-ten-section-d.pdf
Last Reviewed: August 6, 2024
Sample Application (R43): Benjamin Delbert Brooks
https://www.niaid.nih.gov/sites/default/files/R43-Brooks-Application.pdf
Last Reviewed: November 25, 2022
Report of the Advisory Committee on Research on Women’s Health: Fiscal Years 2019–2020
https://www.niaid.nih.gov/sites/default/files/ORWH-Biennial-Report2019-20.pdf
Last Reviewed: March 8, 2022
Sample application (R15): Mohammad Ayoub Mir
https://www.niaid.nih.gov/sites/default/files/R15-Mohammad-Ayoub-Mir-Application.pdf
Last Reviewed: August 4, 2017
Niki M. Moutsopoulos, D.D.S., Ph.D., is Chief of the Laboratory of Host Immunity and Microbiome and the Chief of the Human Barrier Immunity Section.
Last Reviewed: February 20, 2025
Michail Lionakis, M.D., Sc.D., is Chief of the Laboratory of Clinical Immunology and Microbiology and the Chief of the Fungal Pathogenesis Section. The section's research focuses on 1) cellular and molecular factors that regulate the immune response against mucosal and invasive candidiasis and invasive aspergillosis in clinically relevant animal models and 2) better understanding the genetic and immune defects that underlie enhanced susceptibility to mucocutaneous and invasive fungal infections in humans.
Last Reviewed: February 18, 2025
Two U.S. Food and Drug Administration (FDA)–approved mRNA vaccines for COVID-19 have saved millions of lives. These vaccines were developed with NIH support and research on a protein found on SARS-CoV-2, the virus that causes COVID-19. Clinical trials for the COVID-19 vaccines in people were established in what seemed like record time. But in reality, more than 50 years of public and private
Last Reviewed: April 4, 2024
NIAID Biodefense Research Agenda for CDC Category A Agents - 2006 Progress Report
https://www.niaid.nih.gov/sites/default/files/cata_2006.pdf
Last Reviewed: August 6, 2019
Last Reviewed: November 14, 2024
It's a fact of grant life: most applications do not succeed. If yours is one of them at NIH, you need to first spend some time identifying what went wrong.
Last Reviewed: September 13, 2024
Opportunistic fungal infections represent major causes of morbidity and mortality despite the administration of antifungal therapy. A better mechanistic understanding of host-fungal interactions will inform the development of improved immune-based strategies for the prevention, risk stratification, prognostication, vaccination, and treatment of vulnerable patient populations. In the Fungal
Last Reviewed: February 18, 2025
Jordan Report 20th Anniversary: Accelerated Development of Vaccines 2002
https://www.niaid.nih.gov/sites/default/files/jordan20_2002.pdf
Last Reviewed: December 31, 2002